Baxter will acquire Ohmeda anesthetic and critical care pharmaceutical product lines for $104 mil. in cash.
OHMEDA PURCHASE FOR BAXTER OFFERS PAINLESS FIT: $104 MIL. CASH PURCHASE from U.K.-based BOC gives Baxter ownership of Ohmeda's anesthetic gas and critical care pharmaceutical product line that Baxter has marketed in the U.S. since 1995. Baxter said the division will be integrated into the Anesthesia Group of the company's I.V. Systems/Medical Products business.
You may also be interested in...
Baxter is adding about $200 mil. in annual sales to its anesthesia/critical care line via the acquisition of ESI Lederle from Wyeth
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011